DiaMedica Therapeutics (DMAC)

Executive Summary

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on developing DM199, a recombinant human tissue kallikrein-1, for serious ischemic disorders including preeclampsia, fetal growth restriction, and acute ischemic stroke. DM199 is designed to restore vascular health by regulating blood flow and reducing inflammation, addressing significant unmet medical needs in conditions with limited treatment options. The company's lead program in acute ischemic stroke is in a Phase 2/3 trial (ReMEDy2), while a Phase 2 trial (RELIEF) for preeclampsia is ongoing. DiaMedica's approach leverages the body's natural kallikrein-kinin system, offering a novel mechanism distinct from current therapies. As a public company with a market capitalization of approximately $330 million, DiaMedica represents a high-risk, high-reward investment opportunity, with near-term catalysts that could significantly impact its valuation. The company's ability to deliver positive clinical data and navigate regulatory pathways will be critical for its success.

Upcoming Catalysts (preview)

• Q3 2026Top-line results from ReMEDy2 Phase 2/3 acute ischemic stroke trial40% success
• Q4 2026Interim or final data from RELIEF Phase 2 preeclampsia trial35% success
• Q2 2026Regulatory guidance or FDA meeting outcomes for stroke program50% success